Kezar Life Sciences KZR 深 滬
等待開盤 10-18 09:30:00 美东时间
0.816
-0.079
-8.80%
華盛通- 最 高0.86
- 今 開0.86
- 成交量 124.06万股
- 最 低 0.78
- 昨 收 0.8947
- 總市值 5940.59万
- 52周最高 1.135
- 市盈率 靜 --
- 換手率 1.70%
- 52周最低 0.5202
- 委 比 99.29%
- 總股本 7280.14万
- 歷史最高 36.327
- 量 比 2.13
- 振 幅 8.94%
- 歷史最低 0.5202
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kezar stock falls 9% after board rejects Concentra takeover offer
Shares of Kezar Life Sciences (NASDAQ:KZR) fell 9% Thursday after the company said its board of directors had unanimously rejected an unsolicited takeover offer from Concentra Biosciences and adopted ...
10-17 23:58
Kezar receives acquisition proposal from Concentra for $1.10 per share
Biotech company, Kezar Life Sciences (NASDAQ:KZR) said on Thursday that it has received an unsolicited, non-binding proposal from Concentra Biosciences, to acquire all the outstanding shares of Kezar ...
10-10 20:48
康乃德生物盘中异动 股价大跌5.47%
北京时间2024年10月10日00时12分，康乃德生物（CNTB.us）股票出现异动，股价急速下挫5.47%。截至发稿，该股报1.21美元/股，成交量777股...
10-10 00:12
Kezar zetomipzomib IND for lupus placed on FDA clinical hold
Kezar Life Sciences (NASDAQ:KZR) said the FDA has placed a clinical hold on its Investigational New Drug application for zetomipzomib for the treatment of lupus nephritis. The hold comes after Kezar i...
10-05 05:50
Kezar Life Sciences Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
10-02 18:33
快讯 | Kezar Life Sciences 公司：Jefferies 将目标价从$13下调至$3
Kezar Life Sciences Inc : Jefferies Cuts Target Price to $3 From $13
10-01 11:56
快讯 | kezar life sciences报告2024年第二季度财务业绩并提供业务更新
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides ...
08-14 04:02
云顶新耀宣布Zetomipzomib（泽托佐米）治疗活动性狼疮性肾炎的全球2b期...
云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布正在中国推进的zetomipzomib（泽托佐米）治疗...
07-22 07:32
Kezar Life Sciences GAAP EPS of -$0.30
Kezar Life Sciences press release (NASDAQ:KZR): Q1 GAAP EPS of -$0.30. More on Kezar Life Sciences Seeking Alpha’s Quant Rating on Kezar Life Sciences Historical earnings data for Kezar Life Sciences ...
05-10 05:29
Kezar Life Sciences Q1 EPS $(0.30) Beats $(0.33) Estimate
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 3.23 percent increase over losses of $(0.31) per share from
05-10 04:40
